News ArchivesRead News
Ibuprofen may curb risk of Parkinson’s disease
Thursday December 22, 2005
Dec 16, 2005(Reuters Health) - Regular use of the pain-relieving nonsteroidal anti-inflammatory drug (NSAID) ibuprofen (Motrin, Advil) may delay or prevent the onset of Parkinson’s disease, according to data from roughly 147,000 U.S. men and women enrolled in the Cancer Prevention Study II Nutritional Cohort.
In 1992, subjects provided information on four types of commonly used analgesics. In 2001, they provided information on the occurrence of Parkinson’s disease. The researchers detected 413 cases of Parkinson’s disease during follow up.
"We found that individuals who regularly used ibuprofen had about a 35 percent lower risk of developing Parkinson’s disease than non-users," Dr. Alberto Ascherio, of Harvard School of Public Health in Boston, Massachusetts, told Reuters Health.
Specifically, compared to those who did not use NSAIDs, users of 2 to 7 ibuprofen tablets per week had about a 28 percent reduced relative risk of developing Parkinson’s disease, while those who reported using 1 or more tablets per day had a 38 percent reduced risk of Parkinson’s.
No associations were observed between the risk of PD and the use of aspirin, other NSAIDs, or acetaminophen.
"These findings suggest that ibuprofen could contribute to the prevention of Parkinson’s disease," Ascherio said. "Because of the progressive nature of the degenerative process, it is also possible that this drug could be beneficial for individuals with Parkinson’s, but this should be tested in randomized clinical trials."
"It would be premature for people with Parkinson’s disease to start taking ibuprofen or other anti-inflammatory drugs," Ascherio cautioned. "Albeit promising, these findings are insufficient to support a change in current therapeutical practice."
Recent NewsSep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show
Aug 14 - 16 Tips to Increase Your Mobility Confidence While Living With Parkinson’s Disease
Aug 10 - Boxers are fighting back against Parkinson’s
Aug 9 - Parkinson’s Experiment to Be Aboard Next Flight to International Space Station
Aug 9 - Parkinson’s Disease and Sleeping with the Enemy
Aug 7 - The Importance of Oral Health in Parkinson’s Disease
Aug 7 - Researchers Gain Better Insight Into Alpha-Synuclein’s Role in Parkinson’s Disease
Jul 31 - New Digital Cognitive Assessment Tool Receives Positive FDA Review
Jul 20 - Parkinson’s DREAM Challenge Uses Mobile Sensor Data to Monitor Health Based on Movement